May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Complications After Intravitreal Injection of Antiangiogenic Factors
Author Affiliations & Notes
  • J. Callizo
    Ophthalmology, Philipps-University Marburg (Germany), Marburg, Germany
  • S. Mennel
    Ophthalmology, Philipps-University Marburg (Germany), Marburg, Germany
  • C. H. Meyer
    Ophthalmology, Philipps-University Marburg (Germany), Marburg, Germany
  • Footnotes
    Commercial Relationships J. Callizo, None; S. Mennel, None; C.H. Meyer, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3384. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Callizo, S. Mennel, C. H. Meyer; Complications After Intravitreal Injection of Antiangiogenic Factors. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3384.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: Description of complications observed after intravitreal application of Vascular Endothelial Growth Factor (VEGF) inhibitors in patients with choriodal neovascularization, proliferative diabetic retinopathy, retinal venous occlusion, angioid streaks and retinal capillary hemangioma

Methods:: In the last 14 months 524 intravitreal injections in 217 patients were performed. Nineteen (8.7%) patients were treated with pegaptanib (Macugen®), 188 (86.7%) patients with bevacizumab (Avastin®) and 10 (4.6%) patients with ranibizumab (Lucentis®). Each patient received between one and six injections (mean, 2.4 injections). Injections were performed with an interval of four weeks. All patients were controlled at least once a month with anterior segment exploration, funduscopy and OCT

Results:: Complications were observed after 18 (3.4%) injections during the follow-up. Five (0.9%) patients had an acute tear of the retinal pigment epithelium, eight (1.7%) patients suffered a Charles Bonnet syndrome (visual hallucinations), in four (0.9%) cases a subretinal hemorrhage developed and one (0.2%) eye presented a sterile endophthalmitis

Conclusions:: Intravitreal treatment with VEGF inhibitors seems to be a safe therapy for several retinal vascular pathologies.The majority of complications observed were reversible and did not cause a decrease in visual acuity. However, complications may occur and patients should be rigorous informed

Keywords: retinal neovascularization • injection • clinical (human) or epidemiologic studies: outcomes/complications 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.